ECSP13012964A - Tratamientos combinados para neoplasias hematologicas malignas - Google Patents

Tratamientos combinados para neoplasias hematologicas malignas

Info

Publication number
ECSP13012964A
ECSP13012964A ECSP13012964A ECSP13012964A EC SP13012964 A ECSP13012964 A EC SP13012964A EC SP13012964 A ECSP13012964 A EC SP13012964A EC SP13012964 A ECSP13012964 A EC SP13012964A
Authority
EC
Ecuador
Prior art keywords
malign
combined treatments
alkyl
pharmaceutically acceptable
hematological neoplasias
Prior art date
Application number
Other languages
English (en)
Inventor
Langdon Miller
Roger G Ulrich
Michael Gallatin
Neill A Giese
Brian Lannutti
Albert Yu
Thomas M Jahn
Original Assignee
Gilead Calistoga Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45888489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012964(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Calistoga Llc filed Critical Gilead Calistoga Llc
Publication of ECSP13012964A publication Critical patent/ECSP13012964A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Stored Programmes (AREA)

Abstract

La invención proporciona métodos relacionados con una novedosa estrategia terapéutica para el tratamiento de neoplasias hematológicas malignas y enfermedades inflamatorias . En particular, el método consiste en la administración de un compuesto de fórmula A, (A)donde R es H, halo, o C1-C6 alquilo; R' is C1-C6 alquilo; o una sal farmacéuticamente aceptable del mismo; yopcionalmente un excipiente farmacéuticamente aceptable; yuno o más agentes terapéuticos adicionales opcionalmente seleccionados del grupo que comprendebendamustina, rituximab y ofatumumab.
ECSP13012964 2011-03-11 2013-10-10 Tratamientos combinados para neoplasias hematologicas malignas ECSP13012964A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161452034P 2011-03-11 2011-03-11
US201161493317P 2011-06-03 2011-06-03

Publications (1)

Publication Number Publication Date
ECSP13012964A true ECSP13012964A (es) 2014-02-28

Family

ID=45888489

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012964 ECSP13012964A (es) 2011-03-11 2013-10-10 Tratamientos combinados para neoplasias hematologicas malignas

Country Status (22)

Country Link
US (3) US20130064812A1 (es)
EP (2) EP2683377A1 (es)
JP (2) JP2014510729A (es)
KR (1) KR20140022836A (es)
CN (1) CN103826629A (es)
AP (1) AP2013007158A0 (es)
AR (1) AR085668A1 (es)
AU (2) AU2012229266A1 (es)
BR (1) BR112013022801A2 (es)
CA (1) CA2829096A1 (es)
CL (1) CL2013002552A1 (es)
CO (1) CO6821936A2 (es)
CR (1) CR20130517A (es)
EA (1) EA201391263A1 (es)
EC (1) ECSP13012964A (es)
MA (1) MA35090B1 (es)
MX (1) MX2013010439A (es)
PE (1) PE20140405A1 (es)
SG (2) SG10201601909TA (es)
TW (1) TW201242598A (es)
UY (1) UY33947A (es)
WO (1) WO2012125510A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
CA2645766A1 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
WO2009088990A1 (en) 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
AU2009313878B2 (en) 2008-11-13 2016-01-07 Gilead Calistoga Llc Therapies for hematologic malignancies
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
US9737521B2 (en) 2012-11-08 2017-08-22 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
KR20150126042A (ko) 2013-03-12 2015-11-10 다이닛본 스미토모 세이야꾸 가부시끼가이샤 액체 수성 조성물
CN103271897A (zh) * 2013-06-04 2013-09-04 李春启 美司那在制备抗血管生成类药物中的应用
ES2535452B1 (es) * 2013-08-02 2016-03-02 Dalana3 S.L. Potenciación del efecto del metotrexato mediante el uso combinado con estatinas lipofílicas
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
EP3148532B1 (en) 2014-05-28 2021-03-03 Piramal Enterprises Limited Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer
CU24428B1 (es) 2014-07-04 2019-06-04 Lupin Ltd Derivados de quinolizinona como inhibidores de pi3k
CN105380956B (zh) * 2015-11-04 2017-12-19 张陆军 一种治疗白血病的含艾德拉尼的药物组合物及应用
CN109640999A (zh) * 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
CN111670364B (zh) 2017-11-30 2024-02-02 新加坡保健服务集团有限公司 用于将癌症患者分类到合适的癌症治疗组的系统和方法以及治疗癌症患者的组合物
TWI820146B (zh) * 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
CN112569342A (zh) * 2020-12-21 2021-03-30 中南大学 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500338A (ja) * 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
AU2009313878B2 (en) * 2008-11-13 2016-01-07 Gilead Calistoga Llc Therapies for hematologic malignancies
US8546409B2 (en) * 2009-04-20 2013-10-01 Gilead Calistoga Llc Methods of treatment for solid tumors
CA3154024C (en) * 2010-06-03 2024-02-27 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma

Also Published As

Publication number Publication date
BR112013022801A2 (pt) 2019-09-24
SG193337A1 (en) 2013-10-30
MX2013010439A (es) 2014-07-09
MA35090B1 (fr) 2014-05-02
EA201391263A1 (ru) 2014-06-30
US20170119771A1 (en) 2017-05-04
EP2683377A1 (en) 2014-01-15
CN103826629A (zh) 2014-05-28
US20130064812A1 (en) 2013-03-14
AU2012229266A1 (en) 2013-05-02
UY33947A (es) 2012-10-31
SG10201601909TA (en) 2016-04-28
CR20130517A (es) 2014-02-12
CA2829096A1 (en) 2012-09-20
PE20140405A1 (es) 2014-03-22
JP2014510729A (ja) 2014-05-01
WO2012125510A1 (en) 2012-09-20
AU2016228272A1 (en) 2016-10-06
AP2013007158A0 (en) 2013-10-31
TW201242598A (en) 2012-11-01
CO6821936A2 (es) 2013-12-31
JP2016222700A (ja) 2016-12-28
CL2013002552A1 (es) 2014-09-05
EP3187184A1 (en) 2017-07-05
US20150196564A1 (en) 2015-07-16
KR20140022836A (ko) 2014-02-25
AR085668A1 (es) 2013-10-16

Similar Documents

Publication Publication Date Title
ECSP13012964A (es) Tratamientos combinados para neoplasias hematologicas malignas
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
UY32582A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
AR084174A1 (es) Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
EA201101507A1 (ru) Способы лечения солидных опухолей
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
CR20110343A (es) Inhibidores de proteína cinasa
MY185103A (en) Bezylamine derivatives as inhibitors of plasma kallikrein
AR084469A1 (es) Combinaciones de inhibidores de quinasas para el tratamiento del cancer
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
ECSP13012658A (es) Composiciones y métodos para el tratamiento de la mielofibrosis
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
BR112013029999A2 (pt) derivados de tiazol
BR112013007343A2 (pt) métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica
IN2014DN05869A (es)
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
PE20121523A1 (es) Metodo de tratamiento
AR086444A1 (es) Composiciones farmaceuticas y metodos para tratar el cancer
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors